MEI Pharma Management
Management criteria checks 2/4
MEI Pharma's CEO is David Urso, appointed in Jun 2023, has a tenure of less than a year. total yearly compensation is $1.74M, comprised of 29.6% salary and 70.4% bonuses, including company stock and options. directly owns 0.037% of the company’s shares, worth €16.33K. The average tenure of the management team and the board of directors is 1.5 years and 7.8 years respectively.
Key information
David Urso
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 29.6% |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | 1.5yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | n/a | n/a | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | US$2m | US$517k | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | n/a | n/a | -US$64m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | US$2m | US$492k | -US$41m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | n/a | n/a | -US$31m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | US$1m | US$460k | -US$47m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | n/a | n/a | -US$38m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | US$1m | US$426k | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$39m |
| Dec 31 2018 | n/a | n/a | -US$28m |
| Sep 30 2018 | n/a | n/a | -US$46m |
| Jun 30 2018 | US$1m | US$390k | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$25m |
| Dec 31 2017 | n/a | n/a | -US$20m |
| Sep 30 2017 | n/a | n/a | -US$2m |
| Jun 30 2017 | US$671k | US$375k | US$3m |
Compensation vs Market: David's total compensation ($USD1.74M) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Urso (59 yo)
less than a year
Tenure
US$1,744,152
Compensation
Mr. David M. Urso, Esq., JD, serves as Chief Executive Officer, President and Director at MEI Pharma, Inc. since June 2, 2023 and had been its Senior Vice President of Corporate Development from March 2014...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$1.74m | 0.037% € 16.3k | |
| CFO & Secretary | 6.3yrs | US$879.66k | 0.028% € 12.4k | |
| Chief Medical Officer | 7.3yrs | US$1.16m | 0.022% € 9.6k | |
| Vice President of Marketing | 1.5yrs | no data | no data | |
| Chief People Officer | 1.1yrs | no data | no data | |
| Strategic Advisor | 12.1yrs | US$755.98k | 0.025% € 11.2k | |
| Senior Vice President of Corporate Affairs | 2.2yrs | no data | no data | |
| Senior Vice President of Quality | 1.4yrs | no data | no data | |
| Executive Vice President of Finance | less than a year | no data | no data |
1.5yrs
Average Tenure
62yo
Average Age
Experienced Management: MMI0's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$1.74m | 0.037% € 16.3k | |
| Independent Non-Executive Director | 4yrs | US$144.60k | 0% € 0 | |
| Independent Non-Executive Director | 5.4yrs | US$152.10k | 0.028% € 12.4k | |
| Director | 13.3yrs | US$2.53m | 0.31% € 138.3k | |
| Independent Non-Executive Director | 10.1yrs | US$154.16k | 0% € 0 | |
| Independent Director | 1.7yrs | US$124.85k | 0% € 0 | |
| Independent Non-Executive Director | 10.4yrs | US$144.60k | 0.0075% € 3.3k | |
| Independent Non-Executive Chair | 11.8yrs | US$152.10k | 0.083% € 36.8k |
7.8yrs
Average Tenure
63yo
Average Age
Experienced Board: MMI0's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/16 06:38 |
| End of Day Share Price | 2023/04/18 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MEI Pharma, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen V. Byrne | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Gene Mack | Brean Capital |